Synthesis, radiolabeling and stability of new nitrophenol complexes of 99mTc as possible hypoxia imaging radiopharmaceuticals

Jalilian, Amir Reza; Bineshmarvasti, Maria

doi:10.1007/s10967-006-0024-x

Search citation statements

Order By: Relevance

Paper Sections

Select...

Technetium ( 99m Tc)1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2007

2016

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Favoured chelating systems are known by the number of ligand atoms, which can be nitrogen, oxygen, phosphorous and sulfur. Recent examples have been the development of new nitrophenol complexes 168 (N 2 OS) for hypoxia imaging, testosterone derivatives 169 (N 2 S 2 ), and a morpholino antisense oligomer 170 (N 2 S 2 ). As well as such ligands, technetium can also be bound to nitrogen, a diazo group, or a trio of carbon monoxide molecules.…”

Section: Technetium ( 99m Tc)mentioning

confidence: 99%

Radiochemistry

Urch

2007

Annu. Rep. Prog. Chem., Sect. A: Inorg. Chem.

View full text Add to dashboard Cite

Section: Technetium ( 99m Tc)mentioning

confidence: 99%

Radiochemistry

Urch

2007

Annu. Rep. Prog. Chem., Sect. A: Inorg. Chem.

View full text Add to dashboard Cite

An insight into tumoral hypoxia: the radiomarkers and clinical applications

et al. 2009

View full text Add to dashboard Cite

Tumoral hypoxia is related to severe structural abnormalities of tumor microvessels, leading to deteriorated O 2 diffusion. This decreased O 2 concentration in cancer cells compromises cellular functions, besides being responsible for resistance to radiation therapy. Consequently, it is very important to know the hypoxic status of a tumor. In this review, the different methodologies available for evaluating cellular hypoxia in vivo are discussed, particularly those in which the hypoxia information is obtained through imaging. Among these the nuclear medicine approach uses ligands to complex with radionuclides. The resulting radioactive complexes which may be single photon or positron emitters, are very useful as imaging probes. The nature of ligands and their corresponding complexes, with application or potential application as hypoxia detectors, will be described. A summary of the most significant results so far obtained in clinical or preclinical applications will also be discussed.

show abstract